x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011936
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala340 of human CTPS1 protein. Antibodies are purified by peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | CTPS1 |
| UniProt No. | P17812 |
| Gene ID | 1503 |
| Gene Description | CTPS1 catalyzes the conversion of UTP to CTP through ATP-dependent amination. Research studies show that pyrimidine biosynthesis is upregulated in pancreatic cancer cell models of resistance to gemcitabine, a deoxycytidine analog. Increased pyrimidine biosynthesis leads to elevated levels of endogenous dCTP, which outcompetes gemcitabine from incorporating into DNA during replication and, therefore, reduces the anti-cancer effectiveness of gemcitabine. Induction of CTPS1 expression was observed in gemcitabine-resistant pancreatic cancer cell models. Gemcitabine resistance directly correlates with CTPS1 expression levels in various pancreatic cancer cell lines. Furthermore, CTPS1 expression was shown to increase in T cells upon T-cell receptor activation, suggesting a critical role of CTPS1 in the immune system. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
